Advertisement

Search Results

Advertisement



Your search for Sumanta Kumar Pal, MD matches 8 pages

Showing 1 - 8


solid tumors

Expert Point of View: Sumanta Kumar Pal, MD and John V. Heymach, MD, PhD

ASCO spokespersons at the press briefing lauded the results with larotrectinib and called for broader testing for tropomyosin receptor kinase fusions.  The data for larotrectinib “bring us into a new era where treatment is truly based on mutation, not location,” said Sumanta Kumar Pal, MD, a...

solid tumors

ASCO 2017: Larotrectinib Shows Durable Efficacy Across Diverse Pediatric and Adult Cancers

Scientists may have developed the first targeted, oral, tumor-type agnostic therapy—an agent that works comparably well across many kinds of cancer, regardless of patient age. In clinical trials of adults and children with 17 different types of advanced cancer, larotrectinib treatment...

issues in oncology

ASCO 2017: ProfiLER Trial: Routine Genomic Testing Feasible, but Only a Subset of Patients May Benefit

Genomic testing of tumor samples can enable personalized treatment selection, where targeted treatments are matched to genetic changes in the tumor. Although a growing number of patients with advanced cancers receive some genomic testing, comprehensive genomic testing is not yet routine care. A...

prostate cancer

ASCO 2017: LATITUDE Trial: Addition of Abiraterone to Standard Hormonal Therapy Improves Outcomes in Newly Diagnosed Metastatic Prostate Cancer

Adding abiraterone acetate (Zytiga) plus prednisone to standard hormonal therapy for men newly diagnosed with high-risk, metastatic prostate cancer lowers the chance of death by 38%. In a phase III clinical trial of 1,200 men, abiraterone also more than doubled the median time until the cancer...

prostate cancer

ASCO 2017: STAMPEDE Trial: Adding Abiraterone to Standard Treatment Improves Survival in Advanced Prostate Cancer

The STAMPEDE clinical trial of nearly 2,000 men shows that adding abiraterone acetate (Zytiga) to a standard initial treatment regimen for high-risk, advanced prostate cancer lowers the relative risk of death by 37%. The 3-year survival rate was 76% with standard therapy alone vs 83% with standard...

kidney cancer

Adjuvant Sunitinib for Renal Cell Carcinoma: Not Ready for Prime Time

In renal cell carcinoma and other cancer types, a consistent paradigm in drug development exists: Observe efficacy of a drug in the metastatic setting and move quickly to explore the agent in the adjuvant setting. In the cytokine era, there were multiple efforts to characterize whether adjuvant...

solid tumors

ASCO 2016: Liquid Biopsy May Help Guide Treatment Decisions for Patients With Advanced Solid Tumors

A large-scale genomic analysis found that patterns of genetic changes detected in blood samples (liquid biopsy) closely mirror those identified in traditional tumor biopsy. With blood samples from more than 15,000 patients and 50 different tumor types, this is one of the largest cancer genomics...

solid tumors

ASCO 2016: Precision Medicine Approach May Expand Therapeutic Options for Patients

Researchers reported encouraging early results from a phase II trial that matches patients with molecular abnormalities in the tumor to corresponding targeted treatments. Twenty-nine of 129 patients with 12 different types of advanced cancers responded to drugs outside of U.S. Food and Drug...

Advertisement

Advertisement



Advertisement